BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oyer JL, Gitto SB, Altomare DA, Copik AJ. PD-L1 blockade enhances anti-tumor efficacy of NK cells. Oncoimmunology 2018;7:e1509819. [PMID: 30377572 DOI: 10.1080/2162402X.2018.1509819] [Cited by in Crossref: 56] [Cited by in F6Publishing: 37] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang W, Zhao Z, Li F. Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy. Molecular Immunology 2022;144:58-70. [DOI: 10.1016/j.molimm.2022.02.015] [Reference Citation Analysis]
2 Norton KA, Gong C, Jamalian S, Popel AS. Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment. Processes (Basel) 2019;7:37. [PMID: 30701168 DOI: 10.3390/pr7010037] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 15.3] [Reference Citation Analysis]
3 Qiu Q, Lin Y, Ma Y, Li X, Liang J, Chen Z, Liu K, Huang Y, Luo H, Huang R, Luo L. Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy. Front Immunol 2020;11:612202. [PMID: 33488618 DOI: 10.3389/fimmu.2020.612202] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
4 James NE, Woodman M, DiSilvestro PA, Ribeiro JR. The Perfect Combination: Enhancing Patient Response to PD-1-Based Therapies in Epithelial Ovarian Cancer. Cancers (Basel) 2020;12:E2150. [PMID: 32756436 DOI: 10.3390/cancers12082150] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Oh S, Lee JH, Kwack K, Choi SW. Natural Killer Cell Therapy: A New Treatment Paradigm for Solid Tumors. Cancers (Basel) 2019;11:E1534. [PMID: 31614472 DOI: 10.3390/cancers11101534] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
6 de Ruiter EJ, Bisheshar SK, de Roest RH, Wesseling FWR, Hoebers FJP, van den Hout MFCM, Leemans CR, Brakenhoff RH, de Bree R, Terhaard CHJ, Willems SM. Assessing the prognostic value of tumor-infiltrating CD57+ cells in advanced stage head and neck cancer using QuPath digital image analysis. Virchows Arch 2022. [PMID: 35451620 DOI: 10.1007/s00428-022-03323-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lanuza PM, Alonso MH, Hidalgo S, Uranga-murillo I, García-mulero S, Arnau R, Santos C, Sanjuan X, Santiago L, Comas L, Redrado S, Pazo-cid R, Agustin-ferrández MJ, Jaime-sánchez P, Pesini C, Gálvez EM, Ramírez-labrada A, Arias M, Sanz-pamplona R, Pardo J. Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy In Vitro and In Vivo. Front Immunol 2022;13:890836. [DOI: 10.3389/fimmu.2022.890836] [Reference Citation Analysis]
8 Wang F, Wu L, Yin L, Shi H, Gu Y, Xing N. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer. Clin Transl Med 2022;12:e901. [PMID: 35696531 DOI: 10.1002/ctm2.901] [Reference Citation Analysis]
9 Maskalenko NA, Zhigarev D, Campbell KS. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders. Nat Rev Drug Discov 2022. [PMID: 35314852 DOI: 10.1038/s41573-022-00413-7] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Sirait-Fischer E, Olesch C, Fink AF, Berkefeld M, Huard A, Schmid T, Takeda K, Brüne B, Weigert A. Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model. Front Oncol 2020;10:1771. [PMID: 33014872 DOI: 10.3389/fonc.2020.01771] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Toffoli EC, Sheikhi A, Höppner YD, de Kok P, Yazdanpanah-Samani M, Spanholtz J, Verheul HMW, van der Vliet HJ, de Gruijl TD. Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. Cancers (Basel) 2021;13:711. [PMID: 33572396 DOI: 10.3390/cancers13040711] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Ahmad G, Mackenzie GG, Egan J, Amiji MM. DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model. Mol Cancer Ther 2019;18:1961-72. [PMID: 31439714 DOI: 10.1158/1535-7163.MCT-18-1046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
13 Abdolahi S, Ghazvinian Z, Muhammadnejad S, Ahmadvand M, Aghdaei HA, Ebrahimi-Barough S, Ai J, Zali MR, Verdi J, Baghaei K. Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model. Front Pharmacol 2021;12:733075. [PMID: 34588986 DOI: 10.3389/fphar.2021.733075] [Reference Citation Analysis]
14 Ben-Shmuel A, Biber G, Barda-Saad M. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy? Front Immunol 2020;11:275. [PMID: 32153582 DOI: 10.3389/fimmu.2020.00275] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 16.5] [Reference Citation Analysis]
15 Zhang C, Liu Y. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy. Front Immunol 2020;11:1295. [PMID: 32714324 DOI: 10.3389/fimmu.2020.01295] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
16 del Rio M, Perez-simon J, Rodriguez-barbosa J. Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance. Front Immunol 2022;13:887348. [DOI: 10.3389/fimmu.2022.887348] [Reference Citation Analysis]
17 Lee H, Da Silva IP, Palendira U, Scolyer RA, Long GV, Wilmott JS. Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. Cancers (Basel) 2021;13:1363. [PMID: 33802954 DOI: 10.3390/cancers13061363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhao Y, Dong Y, Yang S, Tu Y, Wang C, Li J, Yuan Y, Lian Z. Bioorthogonal Equipping CAR-T Cells with Hyaluronidase and Checkpoint Blocking Antibody for Enhanced Solid Tumor Immunotherapy. ACS Cent Sci 2022;8:603-14. [PMID: 35647274 DOI: 10.1021/acscentsci.2c00163] [Reference Citation Analysis]
19 Qin T, Guo E, Lu F, Fu Y, Liu S, Xiao R, Wu X, Liu C, He C, Wang Z, Qin X, Hu D, You L, Li F, Li X, Huang X, Ma D, Xu X, Yang B, Fan J. Impact of chemotherapy and immunotherapy on the composition and function of immune cells in COVID-19 convalescent with gynecological tumors. Aging (Albany NY) 2021;13:24943-62. [PMID: 34862879 DOI: 10.18632/aging.203739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Shaver KA, Croom-Perez TJ, Copik AJ. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy. Front Immunol 2021;12:679117. [PMID: 33995422 DOI: 10.3389/fimmu.2021.679117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Minetto P, Guolo F, Pesce S, Greppi M, Obino V, Ferretti E, Sivori S, Genova C, Lemoli RM, Marcenaro E. Harnessing NK Cells for Cancer Treatment. Front Immunol 2019;10:2836. [PMID: 31867006 DOI: 10.3389/fimmu.2019.02836] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
22 Sterling C, Webster J. Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia. Am J Hematol 2020;95:529-47. [PMID: 32022292 DOI: 10.1002/ajh.25750] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
23 Zhu H, Liu X. Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies. Front Oncol 2021;11:666340. [PMID: 34434889 DOI: 10.3389/fonc.2021.666340] [Reference Citation Analysis]
24 Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975. [PMID: 32853984 DOI: 10.1016/j.ebiom.2020.102975] [Cited by in Crossref: 73] [Cited by in F6Publishing: 84] [Article Influence: 36.5] [Reference Citation Analysis]
25 Zhang D, Lin Z, Zheng Y, Song J, Li J, Zeng Y, Liu X. Ultrasound-Driven Biomimetic Nanosystem Suppresses Tumor Growth and Metastasis through Sonodynamic Therapy, CO Therapy, and Indoleamine 2,3-Dioxygenase Inhibition. ACS Nano 2020;14:8985-99. [PMID: 32662971 DOI: 10.1021/acsnano.0c03833] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 17.5] [Reference Citation Analysis]
26 Nelli F, Panichi V, Fabbri A, Natoni F, Giannarelli D, Topini G, Virtuoso A, Giron Berrios JR, Marrucci E, Pessina G, Silvestri MA, Ruggeri EM. Dynamic Changes of Peripheral NK Cells Predict Outcome in Patients with PD-L1 Positive Non-small-cell Lung Cancer Undergoing Immune Checkpoint Inhibitors as Second-line Therapy. Cancer Invest 2022;:1-12. [PMID: 35736808 DOI: 10.1080/07357907.2022.2092635] [Reference Citation Analysis]
27 Javed A, Milhem M. Role of Natural Killer Cells in Uveal Melanoma. Cancers (Basel) 2020;12:E3694. [PMID: 33317028 DOI: 10.3390/cancers12123694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Cong J. Metabolism of Natural Killer Cells and Other Innate Lymphoid Cells. Front Immunol 2020;11:1989. [PMID: 32983138 DOI: 10.3389/fimmu.2020.01989] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
29 Choi MG, Kim YJ, Lee JC, Rho JK, Choi CM. Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non-small cell lung cancer. Thorac Cancer 2020;11:3337-45. [PMID: 33017518 DOI: 10.1111/1759-7714.13677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Bai R, Cui J. Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy. Front Immunol 2022;13:886931. [DOI: 10.3389/fimmu.2022.886931] [Reference Citation Analysis]
31 Gemelli M, Noonan DM, Carlini V, Pelosi G, Barberis M, Ricotta R, Albini A. Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer. Front Oncol 2022;12:886440. [DOI: 10.3389/fonc.2022.886440] [Reference Citation Analysis]
32 Nakamura T, Sato T, Endo R, Sasaki S, Takahashi N, Sato Y, Hyodo M, Hayakawa Y, Harashima H. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation. J Immunother Cancer 2021;9:e002852. [PMID: 34215690 DOI: 10.1136/jitc-2021-002852] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Varudkar N, Oyer JL, Copik A, Parks GD. Oncolytic parainfluenza virus combines with NK cells to mediate killing of infected and non-infected lung cancer cells within 3D spheroids: role of type I and type III interferon signaling. J Immunother Cancer 2021;9:e002373. [PMID: 34172515 DOI: 10.1136/jitc-2021-002373] [Reference Citation Analysis]
34 Sun Y, Tan J, Miao Y, Zhang Q. The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury. Cell Commun Signal 2021;19:76. [PMID: 34256773 DOI: 10.1186/s12964-021-00742-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Mortezaee K, Majidpoor J. Checkpoint inhibitor/interleukin-based combination therapy of cancer. Cancer Med 2022. [PMID: 35301813 DOI: 10.1002/cam4.4659] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Asante DB, Morici M, Mohan GRKA, Acheampong E, Spencer I, Lin W, van Miert P, Gibson S, Beasley AB, Ziman M, Calapre L, Meniawy TM, Gray ES. Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients. Cancers (Basel) 2021;13:6225. [PMID: 34944844 DOI: 10.3390/cancers13246225] [Reference Citation Analysis]
37 Yang H, Zhao L, Zhang Y, Li FF. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma. Cancer Med 2021;10:5696-711. [PMID: 34258887 DOI: 10.1002/cam4.4117] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Khan M, Arooj S, Wang H. NK Cell-Based Immune Checkpoint Inhibition. Front Immunol. 2020;11:167. [PMID: 32117298 DOI: 10.3389/fimmu.2020.00167] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 27.0] [Reference Citation Analysis]
39 Khodayari H, Khodayari S, Ebrahimi E, Hadjilooei F, Vesovic M, Mahmoodzadeh H, Saric T, Stücker W, Van Gool S, Hescheler J, Nayernia K. Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors. Cancer Immunol Immunother 2021. [PMID: 34218295 DOI: 10.1007/s00262-021-02975-8] [Reference Citation Analysis]
40 Elahi R, Heidary AH, Hadiloo K, Esmaeilzadeh A. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects. Stem Cell Rev Rep 2021. [PMID: 34472037 DOI: 10.1007/s12015-021-10246-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Nersesian S, Glazebrook H, Toulany J, Grantham SR, Boudreau JE. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. Front Immunol 2019;10:1782. [PMID: 31456796 DOI: 10.3389/fimmu.2019.01782] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
42 Clemen R, Heirman P, Lin A, Bogaerts A, Bekeschus S. Physical Plasma-Treated Skin Cancer Cells Amplify Tumor Cytotoxicity of Human Natural Killer (NK) Cells. Cancers (Basel) 2020;12:E3575. [PMID: 33265951 DOI: 10.3390/cancers12123575] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
43 Korbecki J, Kojder K, Kapczuk P, Kupnicka P, Gawrońska-Szklarz B, Gutowska I, Chlubek D, Baranowska-Bosiacka I. The Effect of Hypoxia on the Expression of CXC Chemokines and CXC Chemokine Receptors-A Review of Literature. Int J Mol Sci 2021;22:E843. [PMID: 33467722 DOI: 10.3390/ijms22020843] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
44 Zheng G, Guo Z, Li W, Xi W, Zuo B, Zhang R, Wen W, Yang AG, Jia L. Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab. Signal Transduct Target Ther 2021;6:236. [PMID: 34158475 DOI: 10.1038/s41392-021-00629-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Khatoon E, Parama D, Kumar A, Alqahtani MS, Abbas M, Girisa S, Sethi G, Kunnumakkara AB. Targeting PD-1/PD-L1 axis as new horizon for ovarian cancer therapy. Life Sci 2022;:120827. [PMID: 35907493 DOI: 10.1016/j.lfs.2022.120827] [Reference Citation Analysis]
46 Bai RL, Chen NF, Li LY, Cui JW. A brand new era of cancer immunotherapy: breakthroughs and challenges. Chin Med J (Engl) 2021;134:1267-75. [PMID: 34039862 DOI: 10.1097/CM9.0000000000001490] [Reference Citation Analysis]
47 Poznanski SM, Ritchie TM, Fan IY, El-Sayes A, Portillo AL, Ben-Avi R, Rojas EA, Chew MV, Shargall Y, Ashkar AA. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy. J Immunother Cancer 2021;9:e001933. [PMID: 33479024 DOI: 10.1136/jitc-2020-001933] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
48 Alvarez M, Simonetta F, Baker J, Morrison AR, Wenokur AS, Pierini A, Berraondo P, Negrin RS. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion. Front Immunol 2020;11:7. [PMID: 32117218 DOI: 10.3389/fimmu.2020.00007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
49 Oyer JL, Croom-Perez TJ, Dieffenthaller TA, Robles-Carillo LD, Gitto SB, Altomare DA, Copik AJ. Cryopreserved PM21-Particle-Expanded Natural Killer Cells Maintain Cytotoxicity and Effector Functions In Vitro and In Vivo. Front Immunol 2022;13:861681. [PMID: 35464440 DOI: 10.3389/fimmu.2022.861681] [Reference Citation Analysis]
50 Bachiller M, Battram AM, Perez-Amill L, Martín-Antonio B. Natural Killer Cells in Immunotherapy: Are We Nearly There? Cancers (Basel) 2020;12:E3139. [PMID: 33120910 DOI: 10.3390/cancers12113139] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
51 Grebić D, Gulić T, Starčević A, Alvirović M, Blagojević Zagorac G, Valković Zujić P, Veljković Vujaklija D. The Role of Innate Immunity in the Pathogenesis of Breast Cancer. Breast Care (Basel) 2021;16:1-5. [PMID: 33716626 DOI: 10.1159/000507314] [Reference Citation Analysis]
52 Shida Y, Nakazawa T, Matsuda R, Morimoto T, Nishimura F, Nakamura M, Maeoka R, Yamada S, Nakagawa I, Park YS, Yasukawa M, Tojo T, Tsujimura T, Nakase H. Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors. Int J Mol Sci 2021;22:9975. [PMID: 34576141 DOI: 10.3390/ijms22189975] [Reference Citation Analysis]
53 Reyes RM, Zhang C, Deng Y, Ji N, Mukherjee N, Padron AS, Clark CA, Svatek RS, Curiel TJ. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation. Oncoimmunology 2021;10:2006529. [PMID: 34858732 DOI: 10.1080/2162402X.2021.2006529] [Reference Citation Analysis]
54 Lin M, Luo H, Liang S, Chen J, Liu A, Niu L, Jiang Y. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. J Clin Invest 2020;130:2560-9. [PMID: 32027620 DOI: 10.1172/JCI132712] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 21.0] [Reference Citation Analysis]
55 Fang F, Wang W, Chen M, Tian Z, Xiao W. Technical advances in NK cell-based cellular immunotherapy. Cancer Biol Med 2019;16:647-54. [PMID: 31908885 DOI: 10.20892/j.issn.2095-3941.2019.0187] [Cited by in F6Publishing: 4] [Reference Citation Analysis]